Adenosine as a modulator of brain activity

Drug News and Perspectives

Volumn 20, Issue 10, 2007, Pages 607-611

  Boison, Detlev ^a,b  

^a RS Dow Neurobiology Laboratories   (United States)

^b LEGACY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; ABT 702; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GP 3269; GP 3966; GW 493838; ISTRADEFYLLINE; NEUROTRANSMITTER; NUCLEOSIDE TRANSPORTER; POLYMER; T 62; UNCLASSIFIED DRUG;

BRAIN FUNCTION; CARDIOVASCULAR EFFECT; CELL THERAPY; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; DOPAMINERGIC TRANSMISSION; DRUG INHIBITION; DRUG TARGETING; ENZYME INHIBITION; EPILEPSY; EPILEPTOGENESIS; GENE THERAPY; HUMAN; MENTAL DISEASE; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PAIN; PARKINSON DISEASE; PATHOLOGY; PRESYNAPTIC NERVE; REVIEW; SEDATION; SEIZURE;

ADENOSINE; ADENOSINE KINASE; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A;

EID: 41149145189     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.10.1181353     Document Type: Review

References (65)

1. Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N. and Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53(4): 527-52.
2. Fredholm, B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007, 14(7): 1315-23.
3. Schiffmann, S.N., Fisone, G., Moresco, R., Cunha, R.A. and Ferre, S. Adenosine A(2A) receptors and basal ganglia physiology. Prog Neurobiol 2007, 83(5): 277-92.
4. Dare, E., Schulte, G., Karovic, O., Hammarberg, C. and Fredholm, B.B. Modulation of glial cell functions by adenosine receptors. Physiol Behav 2007, 92(1-2): 15-20.
5. Fredholm, B.B., Chen, J.F., Cunha, R.A., Svenningsson, P. and Vaugeois, J.M. Adenosine and brain function. Int Rev Neurobiol 2005, 63: 191-270.
6. Fredholm, B.B., Chen, J.F., Masino, S.A. and Vaugeois, J.M. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005, 45: 385-412.
7. Boison, D. Adenosine and epilepsy: From therapeutic rationale to new therapeutic strategies. Neuroscientist 2005, 11(1): 25-36.
8. Hasko, G., Pacher, P., Vizi, E.S. and Illes, P. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005, 26(10): 511-6.
9. Boison, D. Adenosine kinase, epilepsy and stroke: Mechanisms and therapies. Trends Pharmacol Sci 2006, 27(12): 652-8.
10. Dragunow, M. Adenosine: The brain's natural anticonvulsant? Trends Pharmacol Sci 1986, 7: 128.
11. Dunwiddie, T.V. Endogenously released adenosine regulates excitability in the in vitro hippocampus. Epilepsia 1980, 21(5): 541-8.
12. Lee, K.S., Schubert, P. and Heinemann, U. The anticonvulsive action of adenosine: A postsynaptic, dendritic action by a possible endogenous anticonvulsant. Brain Res 1984, 321(1): 160-4.
13. Kochanek, P.M., Vagni, V.A., Janesko, K.L. et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006, 26(4): 565-75.
14. 1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 2006, 200(1): 184-90.
15. Dunwiddie, T.V. and Masino, S.A. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24: 31-55.
16. Huber, A., Güttinger, M., Möhler, H. and Boison, D. Seizure suppression by adenosine A2A receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci Lett 2002, 329(3): 289-92.
17. Monopoli, A., Conti, A., Dionisotti, S., Casati, C., Camaioni, E., Cristalli, G. and Ongini, E. Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneimittelforschung 1994, 44: 1305-12.
18. 1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 2003, 44(7): 877-85.
19. Etherington, L.A. and Frenguelli, B.G. Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner. Eur J Neurosci 2004, 19(9): 2539-50.
20. Boison, D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegener Dis 2007, 4(1): 28-33.
21. 1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol 2005, 193(1): 53-64.
22. Clark, R.S., Carcillo, J.A., Kochanek, P.M.et al. Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans. Neurosurgery 1997, 41(6): 1284-92; discussion 92-3.
23. 1 agonists with diminished hypotensive effects. J Med Chem 1999, 42(18): 3463-77.
24. Olsson, T., Cronberg, T., Rytter, A., Asztely, F., Fredholm, B.B., Smith, M.L. and Wieloch, T. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. Eur J Neurosci 2004, 20(5): 1197-204.
25. Turner, C.P., Seli, M., Ment, L.et al. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci U S A 2003, 100(20): 11718-22.
26. Chen, J.F., Huang, Z., Ma, J.et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999, 19(21): 9192-200.
27. Blum, D., Galas, M.C., Pintor, A.et al. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci 2003, 23(12): 5361-9.
28. de Mendonca, A., Sebastiao, A.M. and Ribeiro, J.A. Adenosine: Does it have a neuroprotective role after all? Brain Res Brain Res Rev 2000, 33(2-3): 258-74.
29. Dixon, A.K., Widdowson, L. and Richardson, P.J. Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum. J Neurochem 1997, 69(2-3): 315-21.
30. Cunha, R.A. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. Purinergic Signal 2005, 1: 111-34.
31. Sebastiao, A.M. and Ribeiro, J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 2000, 21(9): 341-6.
32. Cunha, R.A. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. Purinergic Signal 2005, 1: 111-34.
33. Ciruela, F., Casado, V., Rodrigues, R.J. et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006, 26(7): 2080-7.
34. Sebastiao, A.M. and Ribeiro, J.A. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996, 48(3): 167-89.
35. Gimenez-Llort, L., Fernandez-Teruel, A., Escorihuela, R.M., Fredholm, B.B., Tobena, A., Pekny, M. and Johansson, B. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002, 16(3): 547-50.
36. Martinez-Mir, M.I., Probst, A. and Palacios, J.M. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991, 42(3): 697-706.
37. Pollack, A.E., Harrison, M.B., Wooten, G.F. and Fink, J.S. Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res 1993, 631(1): 161-6.
38. Schiffmann, S.N. and Vanderhaeghen, J.J. Ontogeny of gene expression of adenosine A2 receptor in the striatum: early localization in the patch compartment. J Comp Neurol 1992, 317(2): 117-28.
39. Okada, M., Hirano, T., Mizuno, K. et al. Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res 1997, 28(2): 143-53.
40. Okada, M., Mizuno, K. and Kaneko, S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996, 212(1): 53-6.
41. Zetterstrom, T. and Fillenz, M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 1990, 180(1): 137-43.
42. Fuxe, K., Marcellino, D., Genedani, S. and Agnati, L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov Disord 2007, 22(14): 1990-2017.
43. Fuxe, K., Ferre, S., Genedani, S., Franco, R. and Agnati, L.F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 2007, 92(1-2): 210-7.
44. Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F. and Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006, 29(11): 647-54.
45. Chase, T.N., Bibbiani, F., Bara-Jimenez, W., Dimitrova, T. and Oh-Lee, J.D. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003, 61(11 Suppl. 6): S107-11.
46. Jacobson, K.A. and Gao, Z.G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5(3): 247-64.
47. Bara-Jimenez, W., Sherzai, A., Dimitrova, T.et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61(3): 293-6.
48. Hauser, R.A., Hubble, J.P. and Truong, D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003, 61(3): 297-303.
49. Baldwin, S.A., Beal, P.R., Yao, S.Y., King, A.E., Cass, C.E. and Young, J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004, 447(5): 735-43.
50. Huber, A., Padrun, V., Deglon, N., Aebischer, P., Mohler, H. and Boison, D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A 2001, 98(13): 7611-6.
51. Fedele, D.E., Koch, P., Brüstle, O., Scheurer, L., Simpson, E.M., Mohler, H. and Boison, D. Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett 2004, 370(2-3): 160-5.
52. Fedele, D.E., Gouder, N., Güttinger, M.et al. Astrogliosis in epilepsy leads to overexpression of adenosine kinase resulting in seizure aggravation. Brain 2005, 128(Pt. 10): 2383-95.
53. McGaraughty, S., Cowart, M., Jarvis, M.F. and Berman, R.F. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 2005, 5(1): 43-58.
54. Kowaluk, E.A. and Jarvis, M.F. Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 2000, 9(3): 551-64.
55. Gouder, N., Scheurer, L., Fritschy, J.-M. and Boison, D. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 2004, 24(3): 692-701.
56. McGaraughty, S. and Jarvis, M.F. Purinergic control of neuropathic pain. Drug Development Research 2006, 67: 376-88.
57. Jarvis, M.F., Mikusa, J., Chu, K.L., Wismer, C.T., Honore, P., Kowaluk, E.A. and McGaraughty, S. Comparison of the ability of adenosine kinase inhibitors and adenosine receptor agonists to attenuate thermal hyperalgesia and reduce motor performance in rats. Pharmacol Biochem Behav 2002, 73(3): 573-81.
58. Boison, D., Scheurer, L., Zumsteg, V. et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 2002, 99(10): 6985-90.
59. Erion, M.D., Wiesner, J.B., Rosengren, S., Ugarkar, B.G., Boyer, S.H. and Tsuchiya, M. Therapeutic potential of adenosine kinase inhibitors as analgesic agents. Drug Dev Res 2000, 50: S14-06.
60. Li, T., Steinbeck, J.A., Lusardi, T. et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007, 130(Pt. 5): 1276-88.
61. Eisenach, J.C., Hood, D.D. and Curry, R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002, 96(1): 29-34.
62. Eisenach, J.C., Hood, D.D. and Curry, R. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002, 96(1): 24-8.
63. Kowaluk, E.A., Bhagwat, S.S. and Jarvis, M.F. Adenosine kinase inhibitors. Curr Pharm Des 1998, 4(5): 403-16.
64. Boison, D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 2007, 5: 115-25.
65. Ren, G., Li, T., Lan, J.Q., Wilz, A., Simon, R.P. and Boison, D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 2007, 208(1): 26-37.